Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359448 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL3951230 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL3951233 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL27214135 | 0.87 | CYP2D6 (0.56) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL12173630 | 0.87 | CYP2D6 (0.56) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL14738390 | 0.86 | KMT2A (0.52) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| SCHEMBL14738389 | 0.86 | KMT2A (0.52) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| SCHEMBL26350891 | 0.84 | CYP2D6 (0.58) | ALDH1A1LMNAPOLBCYP2D6KMT2A | |
| SCHEMBL3661459 | 0.84 | CYP2D6 (0.58) | ALDH1A1CYP2D6KMT2AMEN1TAS2R14 | |
| SCHEMBL26114075 | 0.84 | CYP2D6 (0.58) | ALDH1A1CYP2D6KMT2AMEN1TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | ALDH1A1 1213/4885LMNA 2857/4885POLB 3321/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | ALDH1A1 1213/4885LMNA 2857/4885POLB 3321/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | ALDH1A1 3835/4885LMNA 2661/4885POLB 3751/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885LMNA 1656/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.